News & Updates

Show Multimedia Only

Paliperidone 6-month LAI sustains symptomatic, functional remission in schizophrenia at 3 years

18 Oct 2025 by

Patients with schizophrenia who either continued on the LAI paliperidone palmitate (PP) 6-monthly for up to 3 years or transitioned from PP 3-monthly treatment have sustained symptomatic and functional remission, as shown in a post hoc analysis of the single-arm, OLE study PSY3016

Paliperidone 6-month LAI sustains symptomatic, functional remission in schizophrenia at 3 years

18 Oct 2025

Regular fish oil intake tied to lower T2D risk

16 Oct 2025 by

A prospective study evaluating individuals with prediabetes shows an inverse association between habitual fish oil intake and the risk of type 2 diabetes (T2D).

Regular fish oil intake tied to lower T2D risk

16 Oct 2025

Tirzepatide lowers HbA1c, BMI in youth-onset T2D

16 Oct 2025 by

Once-weekly treatment with tirzepatide significantly reduces HbA_1c levels and BMI in children and adolescents with type 2 diabetes (T2D) compared with placebo, according to the SURPASS-PEDS trial presented at EASD 2025.

Tirzepatide lowers HbA1c, BMI in youth-onset T2D

16 Oct 2025

Once-monthly cafraglutide helps with weight loss in adults with obesity

15 Oct 2025

Once-a-month treatment with maridebart cafraglutide—a long-acting peptide–antibody conjugate that combines glucagon-like peptide-1 receptor agonism and glucose-dependent insulinotropic polypeptide receptor antagonism—results in substantial weight reduction in patients with obesity with or without type 2 diabetes, according to a phase II study.

Once-monthly cafraglutide helps with weight loss in adults with obesity

15 Oct 2025

Study finds ethnic disparities in health outcomes, costs in SG

14 Oct 2025 by

Using a dynamic Markov microsimulation model, researchers have found varying disease trajectories and healthcare expenditures by 2050 among adults aged ≥51 years in Singapore.

Study finds ethnic disparities in health outcomes, costs in SG

14 Oct 2025

Optimizing DM management with early insulinization and novel treatments

14 Oct 2025 by

The global diabetes mellitus (DM) epidemic poses significant health challenges in Asia and the rest of the world. At a symposium, Professor Lawrence Leiter of the University of Toronto, Canada, discussed the critical role of early insulinization to reduce long-term complications. He also shared how long-acting insulin analogue injections, such as insulin degludec (IDeg) and its combination with insulin aspart (IDegAsp), which provide longer time in target glucose range with lower hypoglycaemic risks, may help patients achieve long-term treatment goals.

Optimizing DM management with early insulinization and novel treatments

14 Oct 2025

Magnesium confers BP-lowering benefits in people with hypertension, hypomagnesemia

11 Oct 2025

Magnesium supplementation appears to substantially reduce blood pressure (BP) levels in individuals with hypertension and hypomagnesemia, especially those on antihypertensive medication, according to a systematic review and meta-analysis.

Magnesium confers BP-lowering benefits in people with hypertension, hypomagnesemia

11 Oct 2025

Circulating bile acids up risk of CKD in adults with T2D

10 Oct 2025

Higher concentrations of most circulating primary bile acids (PBAs) and total secondary BAs (SBAs) appear to increase the risk of chronic kidney disease (CKD) among adults with type 2 diabetes (T2D), suggests a study.

Circulating bile acids up risk of CKD in adults with T2D

10 Oct 2025

[Infographics] Two patients with dyslipidaemia treated with oral bempedoic acid + ezetimibe FDC

10 Oct 2025 by

Dr Walter Wai-Chee Chan's (Specialist in Cardiology in Hong Kong) cases: one patient with statin-induced autoimmune myositis, and another patient with uncontrolled LDL-C despite maximally tolerated statin + ezetimibe. Find out how these patients responded to and tolerated oral bempedoic acid + ezetimibe fixed-dose combination (FDC) treatment.

[Infographics] Two patients with dyslipidaemia treated with oral bempedoic acid + ezetimibe FDC

10 Oct 2025

Tirzepatide proves safety, efficacy in T1D in real world

09 Oct 2025 by

The use of tirzepatide in a real-world setting demonstrates a favourable safety profile and results in weight loss, lower insulin requirements, and better glycaemic measurements among patients with type 1 diabetes (T1D), as shown in a study presented at EASD 2025.

Tirzepatide proves safety, efficacy in T1D in real world

09 Oct 2025

News & Updates

Filter by Specialty:

Specialty:

Paliperidone 6-month LAI sustains symptomatic, functional remission in schizophrenia at 3 years

Paliperidone 6-month LAI sustains symptomatic, functional remission in schizophrenia at 3 years

Regular fish oil intake tied to lower T2D risk

Regular fish oil intake tied to lower T2D risk

Tirzepatide lowers HbA1c, BMI in youth-onset T2D

Tirzepatide lowers HbA1c, BMI in youth-onset T2D

Once-monthly cafraglutide helps with weight loss in adults with obesity

Once-monthly cafraglutide helps with weight loss in adults with obesity

Study finds ethnic disparities in health outcomes, costs in SG

Study finds ethnic disparities in health outcomes, costs in SG

Optimizing DM management with early insulinization and novel treatments

Optimizing DM management with early insulinization and novel treatments

Magnesium confers BP-lowering benefits in people with hypertension, hypomagnesemia

Magnesium confers BP-lowering benefits in people with hypertension, hypomagnesemia

Circulating bile acids up risk of CKD in adults with T2D

Circulating bile acids up risk of CKD in adults with T2D

[Infographics] Two patients with dyslipidaemia treated with oral bempedoic acid + ezetimibe FDC

[Infographics] Two patients with dyslipidaemia treated with oral bempedoic acid + ezetimibe FDC

Tirzepatide proves safety, efficacy in T1D in real world

Tirzepatide proves safety, efficacy in T1D in real world